{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:04:18Z","timestamp":1788458658286,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to determine the prognostic value of serum uric acid (SUA) on outcomes in heart failure (HF) with preserved ejection fraction (HFpEF), and whether sacubitril\u2013valsartan reduces SUA and use of SUA-related therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We analysed 4795 participants from the Prospective Comparison of ARNI [angiotensin receptor\u2013neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial. We related baseline hyperuricaemia (using age and gender adjusted assay definitions) to the primary outcome [cardiovascular (CV) death and total HF hospitalizations]. We assessed the associations between changes in SUA and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) and other cardiac biomarkers from baseline to 4\u2009months. We simultaneously adjusted for baseline and time-updated SUA to determine whether lowering SUA was associated with clinical benefit. The mean\u2009(\u00b1\u2009standard deviation) age of patients was 73\u2009\u00b1\u20098\u2009years and 52% were women. After multivariable adjustment, hyperuricaemia was associated with increased risk for the primary outcome [rate ratio 1.61, 95% confidence interval (CI) 1.37\u20131.90]. The treatment effect of sacubitril\u2013valsartan for the primary endpoint was not significantly modified by hyperuricaemia (P-value for interaction = 0.14). Sacubitril\u2013valsartan reduced SUA by 0.38\u2009mg\/dL (95% CI 0.31\u22120.45) compared with valsartan at 4 months, with greater effect in those with elevated SUA vs. normal SUA (\u22120.51\u2009mg\/dL vs. \u22120.32\u2009mg\/dL) (P-value for interaction = 0.031). Sacubitril\u2013valsartan reduced the odds of initiating SUA-related treatments by 32% during follow-up (P &amp;lt;\u20090.001). After multivariable adjustment, change in SUA was inversely associated with change in KCCQ-OSS and directly associated with high-sensitivity troponin T (P &amp;lt;\u20090.05). Time-updated SUA was a stronger predictor of adverse outcomes than baseline SUA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum uric acid independently predicted adverse outcomes in HFpEF. Sacubitril\u2013valsartan reduced SUA and the initiation of related therapy compared with valsartan. Reductions in SUA were associated with improved outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1984","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T15:37:07Z","timestamp":1598369827000},"page":"2093-2101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Serum Uric Acid, Influence of Sacubitril\u2013Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF"],"prefix":"10.1093","volume":"22","author":[{"given":"Senthil","family":"Selvaraj","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnian R.","family":"Mc Causland","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina M.","family":"McGrath","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Minnesota , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kober","sequence":"additional","affiliation":[{"name":"Rigshospitalet Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Janssens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospitals , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, German Centre for Cardiovascular Research partner site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Montreal Institute of Cardiology, University of Montreal , Montreal, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor C.","family":"Shi","sequence":"additional","affiliation":[{"name":"Novartis , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"Novartis , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"2026011721375658400_ejhf1984-bib-0001","first-page":"H1123","volume-title":"Am J Physiol Heart Circ Physiol","author":"Shimizu","year":"2015"},{"key":"2026011721375658400_ejhf1984-bib-0002","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0003","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011721375658400_ejhf1984-bib-0004","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0005","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.1056","article-title":"Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0007","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1053\/euhj.1998.1188","article-title":"Uric acid in chronic heart failure: a marker of chronic inflammation","volume":"19","author":"Leyva","year":"1998","journal-title":"Eur Heart J"},{"key":"2026011721375658400_ejhf1984-bib-0008","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/hrt.82.3.348","article-title":"Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure","volume":"82","author":"Leyva","year":"1999","journal-title":"Heart"},{"key":"2026011721375658400_ejhf1984-bib-0009","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/eurjhf\/hfp042","article-title":"Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure","volume":"11","author":"Bergamini","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/hh0302.104531","article-title":"Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart","volume":"90","author":"Saavedra","year":"2002","journal-title":"Circ Res"},{"key":"2026011721375658400_ejhf1984-bib-0011","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/hc4501.098928","article-title":"Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy","volume":"104","author":"Cappola","year":"2001","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0012","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011721375658400_ejhf1984-bib-0013","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2026011721375658400_ejhf1984-bib-0014","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/aje\/kwg260","article-title":"Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987\u20131998","volume":"158","author":"Carnethon","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2026011721375658400_ejhf1984-bib-0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0016","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011721375658400_ejhf1984-bib-0017","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011721375658400_ejhf1984-bib-0018","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026011721375658400_ejhf1984-bib-0019","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"2026011721375658400_ejhf1984-bib-0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026011721375658400_ejhf1984-bib-0021","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0022","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0023","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"key":"2026011721375658400_ejhf1984-bib-0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006125","article-title":"Utility of the cardiovascular physical examination and impact of spironolactone in heart failure with preserved ejection fraction","volume":"12","author":"Selvaraj","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0025","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.amjcard.2019.12.003","article-title":"Prognostic value of serum uric acid in hospitalized heart failure patients with preserved ejection fraction (from the Japanese Nationwide Multicenter Registry)","volume":"125","author":"Kobayashi","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026011721375658400_ejhf1984-bib-0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.03.054","article-title":"Elevated uric acid prevalence and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from RELAX","author":"Carnicelli","year":"2020","journal-title":"Am J Med"},{"key":"2026011721375658400_ejhf1984-bib-0027","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00004872-199917030-00017","article-title":"Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers","volume":"17","author":"Rousso","year":"1999","journal-title":"J Hypertens"},{"key":"2026011721375658400_ejhf1984-bib-0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0029","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02854844","article-title":"Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators","volume":"17","author":"Monterroso","year":"2000","journal-title":"Adv Ther"},{"key":"2026011721375658400_ejhf1984-bib-0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026011721375658400_ejhf1984-bib-0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ehf2.12112","article-title":"Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis","volume":"4","author":"Zhang","year":"2017","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1984","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/11\/2093\/66110838\/eurjhf_22_11_2093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/11\/2093\/66110838\/eurjhf_22_11_2093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:40:24Z","timestamp":1768704024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/11\/2093\/8384532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,30]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1984","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"2020-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}